glp-1 therapy for diabetes Agonists Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH GLP-1 Therapy for Type 2

SMD was chosen as a measure of the difference between groups instead of relying on p-values due to the insensitivity of SMDs to sample size 26

The guide to GLP-1 before and after results covers the broader class perspective

& Han, W

& Castrn, M

The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis

Glycemic Safety Of particular importance given the glucagon receptor agonism component of retatrutide, there were no clinically significant increases in blood glucose or concerning hyperglycemic events despite glucagon's classical glucose-raising effects - confirming that the GLP-1 component successfully counteracts glucagon's impact on glucose homeostasis